Veille Coronavirus - Covid-19
56.2K views | +20 today
Follow
Veille Coronavirus - Covid-19
Your new post is loading...
Scooped by HAS-veille
Scoop.it!

Plus de 75 % des patients âgés de 60 à 80 ans ont reçu une dose de rappel depuis plus de 3 mois. Celle-ci reste efficace contre les formes graves  | Direction de la recherche, des études, de l'éval...

Plus de 75 % des patients âgés de 60 à 80 ans ont reçu une dose de rappel depuis plus de 3 mois. Celle-ci reste efficace contre les formes graves  | Direction de la recherche, des études, de l'éval... | Veille Coronavirus - Covid-19 | Scoop.it
No comment yet.
Scooped by HAS-veille
Scoop.it!

Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants | NEJM

Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants | NEJM | Veille Coronavirus - Covid-19 | Scoop.it
N
No comment yet.
Scooped by HAS-veille
Scoop.it!

Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study - ScienceDirect

Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study - ScienceDirect | Veille Coronavirus - Covid-19 | Scoop.it
Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study
No comment yet.
Scooped by HAS-veille
Scoop.it!

Eurosurveillance | Risk and protective factors for SARS-CoV-2 reinfections, surveillance data, Italy, August 2021 to March 2022

Eurosurveillance | Risk and protective factors for SARS-CoV-2 reinfections, surveillance data, Italy, August 2021 to March 2022 | Veille Coronavirus - Covid-19 | Scoop.it
We explored the risk factors associated with SARS-CoV-2 reinfections in Italy between August 2021 and March 2022. Regardless of the prevalent virus variant, being unvaccinated was the most relevant risk factor for reinfection. The risk of reinfection increased almost 18-fold following emergence of the Omicron variant compared with Delta. A severe first SARS-CoV-2 infection and age over 60 years were significant risk factors for severe reinfection.
No comment yet.
Scooped by HAS-veille
Scoop.it!

CDC recommends Pfizer COVID boosters for kids ages 5 to 11

CDC recommends Pfizer COVID boosters for kids ages 5 to 11 | Veille Coronavirus - Covid-19 | Scoop.it
CDC recommends Pfizer COVID boosters for kids ages 5 to 11
No comment yet.
Scooped by HAS-veille
Scoop.it!

Demographic and Clinical Factors Associated With Anti–SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses | Infectious Diseases | JAMA Network Open | JAMA Network

Demographic and Clinical Factors Associated With Anti–SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses | Infectious Diseases | JAMA Network Open | JAMA Network | Veille Coronavirus - Covid-19 | Scoop.it
This cohort study investigates factors associated with anti–SARS-CoV-2 antibody levels.
No comment yet.
Scooped by HAS-veille
Scoop.it!

JCVI provides interim advice on an autumn COVID-19 booster programme

JCVI provides interim advice on an autumn COVID-19 booster programme | Veille Coronavirus - Covid-19 | Scoop.it
The Joint Committee on Vaccination and Immunisation (JCVI) has provided interim advice to government regarding coronavirus (COVID-19) booster doses this autumn.
No comment yet.
Scooped by HAS-veille
Scoop.it!

Identifying who has long COVID in the USA: a machine learning approach using N3C data

Identifying who has long COVID in the USA: a machine learning approach using N3C data | Veille Coronavirus - Covid-19 | Scoop.it
Patients identified by our models as potentially having long COVID can be interpreted
as patients warranting care at a specialty clinic for long COVID, which is an essential
proxy for long COVID diagnosis as its definition continues to evolve. We also achieve
the urgent goal of identifying potential long COVID in patients for clinical trials.
As more data sources are identified, our models can be retrained and tuned based on
the needs of individual studies.
No comment yet.
Scooped by HAS-veille
Scoop.it!

Co-infection with SARS-CoV-2 Omicron and Delta variants revealed by genomic surveillance | Nature Communications

Co-infection with SARS-CoV-2 Omicron and Delta variants revealed by genomic surveillance | Nature Communications | Veille Coronavirus - Covid-19 | Scoop.it
Co-infections with different variants of SARS-CoV-2 are a key precursor to recombination events that are likely to drive SARS-CoV-2 evolution. Rapid identification of such co-infections is required to determine their frequency in the community, particularly in populations at-risk of severe COVID-19, which have already been identified as incubators for punctuated evolutionary events. However, limited data and tools are currently available to detect and characterise the SARS-CoV-2 co-infections associated with recognised variants of concern. Here we describe co-infection with the SARS-CoV-2 variants of concern Omicron and Delta in two epidemiologically unrelated adult patients with chronic kidney disease requiring maintenance haemodialysis. Both variants were co-circulating in the community at the time of detection. Genomic surveillance based on amplicon- and probe-based sequencing using short- and long-read technologies identified and quantified subpopulations of Delta and Omicron viruses in respiratory samples. These findings highlight the importance of integrated genomic surveillance in vulnerable populations and provide diagnostic pathways to recognise SARS-CoV-2 co-infection using genomic data. Here, using genomic approaches, Rockett et al. identify Omicron and Delta SARS-CoV-2 co-infections in two adults, highlighting the usefulness of genomic surveillance for the timely recognition of co-infections in situations when different variants of the virus are circulating in the community.
No comment yet.
Scooped by HAS-veille
Scoop.it!

Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants | NEJM

Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants | NEJM | Veille Coronavirus - Covid-19 | Scoop.it
Neutralization of Deltacron and BA.3 SARS-CoV-2 Variants A small study assessed the neutralization of pseudoviruses composed of the recombinant deltacron and omicron BA.3 variants. BA.3 did no
No comment yet.
Scooped by HAS-veille
Scoop.it!

Unexplained post-acute infection syndromes | Nature Medicine

Unexplained post-acute infection syndromes | Nature Medicine | Veille Coronavirus - Covid-19 | Scoop.it
SARS-CoV-2 is not unique in its ability to cause post-acute sequelae; certain acute infections have long been associated with an unexplained chronic disability in a minority of patients. These post-acute infection syndromes (PAISs) represent a substantial healthcare burden, but there is a lack of understanding of the underlying mechanisms, representing a significant blind spot in the field of medicine. The relatively similar symptom profiles of individual PAISs, irrespective of the infectious agent, as well as the overlap of clinical features with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), suggest the potential involvement of a common etiopathogenesis. In this Review, we summarize what is known about unexplained PAISs, provide context for post-acute sequelae of SARS-CoV-2 infection (PASC), and delineate the need for basic biomedical research into the underlying mechanisms behind this group of enigmatic chronic illnesses. Certain acute infections (including SARS-CoV-2) are associated with an unexplained chronic disability in a minority of patients; this Review summarizes what is known about these understudied and complex illnesses.
No comment yet.
Scooped by HAS-veille
Scoop.it!

Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study | The BMJ

Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study | The BMJ | Veille Coronavirus - Covid-19 | Scoop.it
No comment yet.
Scooped by HAS-veille
Scoop.it!

How can Covid-19 affect the human brain? | Financial Times

How can Covid-19 affect the human brain? | Financial Times | Veille Coronavirus - Covid-19 | Scoop.it
Scientists are trying to understand the cause of neurological effects and whether symptoms will be long-lasting
No comment yet.
Scooped by HAS-veille
Scoop.it!

JCVI interim statement on COVID-19 autumn 2022 vaccination programme

JCVI interim statement on COVID-19 autumn 2022 vaccination programme | Veille Coronavirus - Covid-19 | Scoop.it
Joint Committee on Vaccination and Immunisation (JCVI) interim statement on the COVID-19 vaccination programme for autumn 2022
No comment yet.
Scooped by HAS-veille
Scoop.it!

Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults | NEJM

Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults | NEJM | Veille Coronavirus - Covid-19 | Scoop.it
Omicron Infection in Canada With the emergence of the omicron variant of SARS-CoV-2 in November 2021, these investigators found how rapidly it had spread across Canada among both vaccinated an
No comment yet.
Scooped by HAS-veille
Scoop.it!

Eurosurveillance | Hospitalised patients with breakthrough COVID-19 following vaccination during two distinct waves in Israel, January to August 2021: a multicentre comparative cohort study

Eurosurveillance | Hospitalised patients with breakthrough COVID-19 following vaccination during two distinct waves in Israel, January to August 2021: a multicentre comparative cohort study | Veille Coronavirus - Covid-19 | Scoop.it
Background
Changing patterns of vaccine breakthrough can clarify vaccine effectiveness.
Aim
To compare breakthrough infections during a SARS-CoV-2 Delta wave vs unvaccinated inpatients, and an earlier Alpha wave.
Methods
In an observational multicentre cohort study in Israel, hospitalised COVID-19 patients were divided into three cohorts: breakthrough infections in Comirnaty-vaccinated patients (VD; Jun–Aug 2021) and unvaccinated cases during the Delta wave (ND) and breakthrough infections during an earlier Alpha wave (VA; Jan–Apr 2021). Primary outcome was death or ventilation.
Results
We included 343 VD, 162 ND and 172 VA patients. VD were more likely older (OR: 1.06; 95% CI: 1.05–1.08), men (OR: 1.6; 95% CI: 1.0–2.5) and immunosuppressed (OR: 2.5; 95% CI: 1.1–5.5) vs ND. Median time between second vaccine dose and admission was 179 days (IQR: 166–187) in VD vs 41 days (IQR: 28–57.5) in VA. VD patients were less likely to be men (OR: 0.6; 95% CI: 0.4–0.9), immunosuppressed (OR: 0.3; 95% CI: 0.2–0.5) or have congestive heart failure (OR: 0.6; 95% CI: 0.3–0.9) vs VA. The outcome was similar between all cohorts and affected by age and immunosuppression and not by vaccination, variant or time from vaccination.
Conclusions
Vaccination was protective during the Delta variant wave, as suggested by older age and greater immunosuppression in vaccinated breakthrough vs unvaccinated inpatients. Nevertheless, compared with an earlier post-vaccination period, breakthrough infections 6 months post-vaccination occurred in healthier patients. Thus, waning immunity increased vulnerability during the Delta wave, which suggests boosters as a countermeasure.
No comment yet.
Scooped by HAS-veille
Scoop.it!

Eurosurveillance | mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveil...

Eurosurveillance | mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveil... | Veille Coronavirus - Covid-19 | Scoop.it
For the period of predominance of SARS-CoV-2 Omicron variant in Slovenia, February to March 2022, we estimated mRNA vaccine effectiveness (VE) against severe acute respiratory infection (SARI) COVID-19 using surveillance data. In the most vulnerable age group comprising individuals aged 65 years and more, VE against SARI COVID-19 was 95% (95% CI: 95–96%) for those vaccinated with three doses, in comparison to 82% (95% CI: 79–84%) for those vaccinated with two doses. Such levels of protection were maintained for at least 6 months.
No comment yet.
Scooped by HAS-veille
Scoop.it!

RISK-BASED COST-BENEFIT ANALYSIS OF ALTERNATIVE VACCINES AGAINST COVID-19 IN BRAZIL: CoronaVac VS. AstraZeneca VS. Pfizer - ScienceDirect

RISK-BASED COST-BENEFIT ANALYSIS OF ALTERNATIVE VACCINES AGAINST COVID-19 IN BRAZIL: CoronaVac VS. AstraZeneca VS. Pfizer - ScienceDirect | Veille Coronavirus - Covid-19 | Scoop.it
We propose a probabilistic model to quantify the cost-benefit of mass Vaccination Scenarios (VSs) against COVID-19. Through this approach, we conduct …
No comment yet.
Scooped by HAS-veille
Scoop.it!

Severity and Incidence of Multisystem Inflammatory Syndrome in Children During 3 SARS-CoV-2 Pandemic Waves in Israel | Global Health | JAMA | JAMA Network

Severity and Incidence of Multisystem Inflammatory Syndrome in Children During 3 SARS-CoV-2 Pandemic Waves in Israel | Global Health | JAMA | JAMA Network | Veille Coronavirus - Covid-19 | Scoop.it
This study examines outcomes of multisystem inflammatory syndrome in children during the Alpha, Delta, and Omicron variant waves of the COVID-19 pandemic in Israel.
No comment yet.
Scooped by HAS-veille
Scoop.it!

Covid-19: Second boosters may benefit at-risk groups but have “minimal” impact for others, says WHO | The BMJ

No comment yet.
Scooped by HAS-veille
Scoop.it!

Prescrire - Tous les articles en Une ''Covid-19 : retards dans d'autres soins'', 1er mai 2022

Prescrire - Tous les articles en Une ''Covid-19 : retards dans d'autres soins'', 1er mai 2022 | Veille Coronavirus - Covid-19 | Scoop.it
Tous les articles en Une
No comment yet.
Scooped by HAS-veille
Scoop.it!

Importance of sex and gender factors for COVID-19 infection and hospitalisation: a sex-stratified analysis using machine learning in UK Biobank data | BMJ Open

No comment yet.
Scooped by HAS-veille
Scoop.it!

Safety of COVID-19 Vaccination in US Children Ages 5–11 Years | Pediatrics

BACKGROUND AND OBJECTIVES. Limited post-authorization safety data for BNT-162b2 COVID-19 vaccination among children ages 5–11 years are available, particularly for the adverse event myocarditis, which has been detected in adolescents and young adults. We describe adverse events observed during the first 4 months of the US COVID-19 vaccination program in this age group.METHODS. We analyzed data from 3 US safety monitoring systems: v-safe, a voluntary smartphone-based system that monitors reactions and health effects; the Vaccine Adverse Events Reporting System (VAERS), the national spontaneous reporting system co-managed by CDC and FDA; and the Vaccine Safety Datalink (VSD), an active surveillance system that monitors electronic health records for prespecified events, including myocarditis.RESULTS. Among 48,795 children ages 5–11 years enrolled in v-safe, most reported reactions were mild-to-moderate, most frequently reported the day after vaccination, and were more common after dose 2. VAERS received 7,578 adverse event reports; 97% were non-serious. On review of 194 serious VAERS reports, 15 myocarditis cases were verified; 8 occurred in males after dose 2 (reporting rate 2.2 per million doses). In VSD, no safety signals were detected in weekly sequential monitoring after administration of 726,820 doses.CONCLUSIONS. Safety findings for BNT-162b2 vaccine from 3 US monitoring systems in children ages 5–11 years show that most reported adverse events were mild and no safety signals were observed in active surveillance. VAERS reporting rates of myocarditis after dose 2 in this age group were substantially lower than those observed among adolescents ages 12–15 years.
No comment yet.